Amorfix Life Science (ARFXF) 0.1586 $ARFXF
ProMIS Neurosciences Announces Identification of Multiple Product Candidates Targeting Alzheimer's Disease
PRWeb - Thu Jun 02, 6:09AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that multiple unique therapeutic candidates have successfully completed the screening stage of validation, and will be further developed as potential treatments for Alzheimer's disease (AD). These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aβ), which are widely believed to play a key role in the development and progression of AD.
ProMIS Neurosciences announces identification of multiple product candidates targeting Alzheimer's disease
CNW Group - Thu Jun 02, 6:00AM CDT
Novel therapeutic candidates designed to specifically target the neurotoxic, prion-like strains of misfolded Amyloid beta
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces First Quarter 2016 Results
PRWeb - Wed May 11, 6:10AM CDT
Recent Corporate Highlights
ProMIS Neurosciences announces first quarter 2016 results
CNW Group - Wed May 11, 6:00AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company" today announced its operational and financial results for the three months ended March 31, 2016.
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences announces identification of a fourth novel therapeutic target for Alzheimer's disease
CNW Group - Thu May 05, 6:00AM CDT
Novel target is fourth in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences to Present at the Toronto Microcap Conference
CNW Group - Tue Apr 05, 7:30AM CDT
The Microcap Conference is excited to announce that ProMIS Neurosciences (ticker: PMN.TO) will be presenting to investors on April 12th at the Hilton Toronto. ProMIS Neurosciences will also be available for one-on-one meetings with investors. The Microcap Conference aims to bring together a very selective group of high quality companies and some of the best investors in the micro-cap space. Registration as well as one-on-one scheduling is available at www.microcapconf.com.
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences, Inc. Completes First Tranche of its Private Placement
PRWeb - Wed Mar 30, 6:06AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company" today announced that it has completed the first tranche of its non-brokered private placement (the "Private Placement" (refer to the Company's February 23, 2016 press release). The Company issued a total of 10,803,676 common shares at $0.06 per share for gross proceeds of CDN $648,221.
ProMIS Neurosciences Announces FY2015 Year End Results
PRWeb - Wed Mar 23, 6:07AM CDT
Recent Corporate Highlights
ProMIS Neurosciences announces FY2015 year end results
CNW Group - Wed Mar 23, 6:00AM CDT
TSX: PMN
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces Identification of a Third Novel Therapeutic Target for Alzheimer's Disease
PRWeb - Fri Mar 18, 6:00AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company" today announced that, following the identification of its first two targets announced on November 12, 2015 and February 3, 2016, it has identified a third in a series of novel potential therapeutic targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's disease ("AD" .
ProMIS Neurosciences announces identification of a third novel therapeutic target for Alzheimer's disease
CNW Group - Fri Mar 18, 6:00AM CDT
TSX: PMN
PMN.TO: 0.16 (-0.04)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.40 (-0.08), DRNA: 3.18 (-0.03), INCY: 77.96 (+0.36), LLY: 72.92 (+0.35), STML: 6.96 (-0.10), SNTA: 0.31 (unch), ANTH: 3.07 (-0.01), EXEL: 7.79 (+0.12)
ProMIS Neurosciences Announces Identification of a Second Novel Therapeutic Target for Alzheimer's Disease
PRWeb - Wed Feb 03, 6:03AM CST
ProMIS Neurosciences is currently in the process of identifying and validating a series of potential targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer's disease. The Company plans to use these targets to create specific monoclonal antibody therapeutics for Alzheimer's.
ProMIS Neurosciences announces identification of a second novel therapeutic target for Alzheimer's disease
CNW Group - Wed Feb 03, 6:00AM CST
Novel target is second in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (-0.04)
ProMIS(TM) Neurosciences announces formation of prestigious Scientific Advisory and Business Advisory Boards
CNW Group - Tue Jan 26, 6:10AM CST
TSX: PMN
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces Formation of Prestigious Scientific Advisory and Business Advisory Boards
PRWeb - Tue Jan 26, 6:06AM CST
ProMIS™ Neurosciences, dedicated to development of precision medicine therapeutics for neurodegenerative diseases is pleased to announce the formation of its two key advisory boards to accelerate company development. ProMIS' first products will focus on more effective treatment of Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS). ProMIS Neurosciences is currently in the process of identifying and validating epitopes specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer's disease.
VYGR: 11.88 (-1.26)
ProMIS Neurosciences Adopts Shareholder Rights Plan
PRWeb - Mon Jan 25, 6:02AM CST
ProMIS Neurosciences Inc. (the "Corporation" (PMN: TSX) announces that its board of directors ("Board" has adopted a shareholder rights plan (the "Rights Plan" .
ProMIS Neurosciences adopts shareholder rights plan
CNW Group - Mon Jan 25, 6:00AM CST
ProMIS Neurosciences Inc. (the "Corporation" (PMN: TSX) announces that its board of directors ("Board" has adopted a shareholder rights plan (the "Rights Plan" .
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces Acquisition of Exclusive Worldwide License to Novel Therapeutic Target for Alzheimer's Disease
PRWeb - Thu Nov 12, 6:30AM CST
Pursuant to its expanded license agreement with the University of British Columbia, as announced on Oct. 8, 2015, ProMIS Neurosciences, Inc. announces today that it has acquired an exclusive, worldwide license to a novel Alzheimer's disease target. A provisional patent application for this target was submitted to the United States Patent Office on Monday, Nov. 9, 2015. The amino acid sequence of this novel target has not been disclosed.
ProMIS Neurosciences announces acquisition of exclusive worldwide license to novel therapeutic target for Alzheimer's disease
CNW Group - Thu Nov 12, 6:30AM CST
Novel target is on misfolded beta Amyloid, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces Identification of Multiple Product Candidates Targeting Alzheimer's Disease
PRWeb - Thu Jun 02, 6:09AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that multiple unique therapeutic candidates have successfully completed the screening stage of validation, and will be further developed as potential treatments for Alzheimer's disease (AD). These monoclonal antibody (mab) therapeutics selectively bind to distinct epitope targets specific for the neurotoxic, prion-like strains of misfolded Amyloid beta (Aβ), which are widely believed to play a key role in the development and progression of AD. ProMIS Neurosciences announces identification of multiple product candidates targeting Alzheimer's disease
CNW Group - Thu Jun 02, 6:00AM CDT
Novel therapeutic candidates designed to specifically target the neurotoxic, prion-like strains of misfolded Amyloid beta
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces First Quarter 2016 Results
PRWeb - Wed May 11, 6:10AM CDT
Recent Corporate Highlights
ProMIS Neurosciences announces first quarter 2016 results
CNW Group - Wed May 11, 6:00AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"
today announced its operational and financial results for the three months ended March 31, 2016. PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences announces identification of a fourth novel therapeutic target for Alzheimer's disease
CNW Group - Thu May 05, 6:00AM CDT
Novel target is fourth in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences to Present at the Toronto Microcap Conference
CNW Group - Tue Apr 05, 7:30AM CDT
The Microcap Conference is excited to announce that ProMIS Neurosciences (ticker: PMN.TO) will be presenting to investors on April 12th at the Hilton Toronto. ProMIS Neurosciences will also be available for one-on-one meetings with investors. The Microcap Conference aims to bring together a very selective group of high quality companies and some of the best investors in the micro-cap space. Registration as well as one-on-one scheduling is available at www.microcapconf.com.
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences, Inc. Completes First Tranche of its Private Placement
PRWeb - Wed Mar 30, 6:06AM CDT
ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"
today announced that it has completed the first tranche of its non-brokered private placement (the "Private Placement" (refer to the Company's February 23, 2016 press release). The Company issued a total of 10,803,676 common shares at $0.06 per share for gross proceeds of CDN $648,221. ProMIS Neurosciences Announces FY2015 Year End Results
PRWeb - Wed Mar 23, 6:07AM CDT
Recent Corporate Highlights
ProMIS Neurosciences announces FY2015 year end results
CNW Group - Wed Mar 23, 6:00AM CDT
TSX: PMN
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces Identification of a Third Novel Therapeutic Target for Alzheimer's Disease
PRWeb - Fri Mar 18, 6:00AM CDT
ProMIS Neurosciences ("ProMIS" or the "Company"
today announced that, following the identification of its first two targets announced on November 12, 2015 and February 3, 2016, it has identified a third in a series of novel potential therapeutic targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's disease ("AD" . ProMIS Neurosciences announces identification of a third novel therapeutic target for Alzheimer's disease
CNW Group - Fri Mar 18, 6:00AM CDT
TSX: PMN
PMN.TO: 0.16 (-0.04)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.40 (-0.08), DRNA: 3.18 (-0.03), INCY: 77.96 (+0.36), LLY: 72.92 (+0.35), STML: 6.96 (-0.10), SNTA: 0.31 (unch), ANTH: 3.07 (-0.01), EXEL: 7.79 (+0.12)
ProMIS Neurosciences Announces Identification of a Second Novel Therapeutic Target for Alzheimer's Disease
PRWeb - Wed Feb 03, 6:03AM CST
ProMIS Neurosciences is currently in the process of identifying and validating a series of potential targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer's disease. The Company plans to use these targets to create specific monoclonal antibody therapeutics for Alzheimer's.
ProMIS Neurosciences announces identification of a second novel therapeutic target for Alzheimer's disease
CNW Group - Wed Feb 03, 6:00AM CST
Novel target is second in a series of potential targets on strains of misfolded Amyloid beta, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (-0.04)
ProMIS(TM) Neurosciences announces formation of prestigious Scientific Advisory and Business Advisory Boards
CNW Group - Tue Jan 26, 6:10AM CST
TSX: PMN
PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces Formation of Prestigious Scientific Advisory and Business Advisory Boards
PRWeb - Tue Jan 26, 6:06AM CST
ProMIS™ Neurosciences, dedicated to development of precision medicine therapeutics for neurodegenerative diseases is pleased to announce the formation of its two key advisory boards to accelerate company development. ProMIS' first products will focus on more effective treatment of Alzheimer's Disease (AD) and Amyotrophic Lateral Sclerosis (ALS). ProMIS Neurosciences is currently in the process of identifying and validating epitopes specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer's disease.
VYGR: 11.88 (-1.26)
ProMIS Neurosciences Adopts Shareholder Rights Plan
PRWeb - Mon Jan 25, 6:02AM CST
ProMIS Neurosciences Inc. (the "Corporation"
(PMN: TSX) announces that its board of directors ("Board" has adopted a shareholder rights plan (the "Rights Plan" . ProMIS Neurosciences adopts shareholder rights plan
CNW Group - Mon Jan 25, 6:00AM CST
ProMIS Neurosciences Inc. (the "Corporation"
(PMN: TSX) announces that its board of directors ("Board" has adopted a shareholder rights plan (the "Rights Plan" . PMN.TO: 0.16 (-0.04)
ProMIS Neurosciences Announces Acquisition of Exclusive Worldwide License to Novel Therapeutic Target for Alzheimer's Disease
PRWeb - Thu Nov 12, 6:30AM CST
Pursuant to its expanded license agreement with the University of British Columbia, as announced on Oct. 8, 2015, ProMIS Neurosciences, Inc. announces today that it has acquired an exclusive, worldwide license to a novel Alzheimer's disease target. A provisional patent application for this target was submitted to the United States Patent Office on Monday, Nov. 9, 2015. The amino acid sequence of this novel target has not been disclosed.
ProMIS Neurosciences announces acquisition of exclusive worldwide license to novel therapeutic target for Alzheimer's disease
CNW Group - Thu Nov 12, 6:30AM CST
Novel target is on misfolded beta Amyloid, implicated in the development and progression of Alzheimer's
PMN.TO: 0.16 (-0.04)
